BACKGROUND Company: Leading pharmaceutical company with large and diverse therapeutic pipeline Therapeutic area: Oncology Indication: Multiple types of cancer Phase: I, II, and III CHALLENGE The sponsor was running cardiac safety monitoring for 18 oncology drug studies over the course of 13 years, three of which were pediatric studies. These involved many global sites across five continents. The studies involved a unique compound designed to treat a variety of cancers. Due to the potential for chemotherapy drugs to negatively impact patient heart health and the resulting FDA requirements for cardiovascular safety monitoring, the sponsor required an experienced cardiac safety and imaging partner. To meet the needs of the range of studies, the sponsor sought out a partner they could

Join for free to read